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TNon-small cell lung cancer in
young patients -- A
retrospective analysis of 10
years in a tertiary university
hospital
Dear  Editor,
Non-small  cell  lung  cancer  (NSCLC)  in  young  adults  is
uncommon.  Although  there  is  limited  data  about  clinical
presentation  and  outcomes,  it  does  seem  that  this  popu-
lation  has  some  distinct  clinicopathological  characteristics
and  given  the  signiﬁcant  socio-economic  implications  NSCLC
in  young  adults  is  increasingly  important.1--3
The  authors  report  the  incidence,  clinical  characteristics,
treatment  and  prognosis  of  NSCLC  in  young  patients  (≤45
years),  in  a  tertiary  academic  hospital  in  Oporto.  We  ret-
rospectively  evaluated  2430  patients  newly  diagnosed  with
lung  cancer,  from  January  2005  to  December  2014.  Our  study
identiﬁed  78  (3.2%)  young  adults.  For  analysis  purpose,  it
only  included  patients  with  NSCLC  who  were  followed  up  in
our  center.
Fifty-nine  (75.6%)  young  adults  were  included:  37  (62.7%)
were  male  with  a  mean  age  of  40.8  years  (SD  ±  3.8).  40
(67.8%)  patients  of  the  patients  had  a  history  of  smoking.
The  median  time  from  symptom  onset  to  diagnosis  was
1.0  months  (0--12.0).  Adenocarcinoma  was  the  most  com-
mon  histopathological  type,  recorded  in  44  (74.6%)  patients,
followed  by  squamous  cell  carcinoma  in  7  (11.9%).  EGFR
mutations  and  ALK  translocation  were  recorded  in  only  11
(18.7%)  patients,  and  EGFR  activating  mutations  were  found
in  2  (18.2%).  The  clinical  staging  revealed  5  (8.5%)  patients
with  NSCLC  in  stages  I  and  II,  6  (10.2%)  III-A  and  48  (81.4%)
III-B  and  IV.  The  initial  Performance  Status  (PS)  was  0  and
1  in  41  (69.5%)  patients,  2  in  6  (10.2%),  and  3  and  4  in  8
(13.6%).
Surgical  resection  was  performed  in  9  (15.3%)  patients,
of  whom  7  received  chemotherapy  and  2  received  chemo-
radiotherapy.  In  patients  undergoing  to  surgery,  lobectomy
and  mediastinal  lymph  node  dissection  was  performed  in  7
and  pneumonectomy  in  2.  Chemotherapy  alone  was  given  to
32  (54.2%)  patients  and  combination  chemo-radiotherapy  to
11  (18.6%).  Platinum-based  doublet  regimens  were  used  as
ﬁrst-line  chemotherapy  in  more  than  two  thirds  of  patients
F
p
pn  =  41).  After  progression,  half  of  the  patients  (n  =  29)
ere  treated  with  second-line  chemotherapy  and  18.6%
n  =  11)  patients  to  third-line.  A  minority  (11.9%)  of  patients
eceived  best  supportive  care  (BSC)  as  initial  treatment.
egarding  response  to  ﬁrst-line  treatment,  5  (8.5%)  patients
btained  a  complete  response,  8  (13.6%)  obtained  a  par-
ial  response,  3  (5.1%)  stabilized,  and  the  majority  (72.9%)
rogressed.  The  median  progression-free  survival  was  4.0
onths  (0--39.0).
During  the  follow-up  period  only  12  (20.3%)  patients  were
till  alive.  In  Kaplan--Meier  analyses,  the  median  survival
ate  was  about  1.5  months  in  BSC  group  and  9.0  months
n  those  submitted  to  other  non-surgical  treatments.  Six
66.7%)  operated  patients  are  still  alive  (Fig.  1).
Lung  cancer  is  considered  a  disease  of  the  elderly.
he  incidence  among  young  adults  has  been  found  to  be
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ig.  1  Kaplan--Meier  survival  curves  according  to  treatment
erformed  (surgery,  other  non-surgical  treatments  and  best  sup-
ortive  care).
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around  5.3%;  however,  previous  reports  have  shown  trends  of
increasing  incidence  rates.4 However,  in  our  study  we  found
a  lower  incidence  (3.2%).  Patients  who  developed  NSCLC  at
a  young  age  may  have  other  unknown  risk  factors  in  addition
to  inherited  risk.3
Adenocarcinoma  was  the  most  common  histopathological
type  in  this  group,  conﬁrming  previously  published  series.1--5
The  majority  of  patients  presented  with  advanced  stage  dis-
ease  at  diagnosis,  despite  a  good  PS.  Unfortunately,  for  most
of  the  study  period  the  patients  were  not  screened  for  driver
mutations  so  the  platinum-based  doublet  was  the  most  fre-
quently  used  treatment  scheme.  There  are  conﬂicting  data
regarding  prognosis  in  this  group  when  comparing  them  with
older  adults.1--5 In  our  study,  despite  the  aggressive  treat-
ment,  the  prognosis  was  poor.
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Not yet known side effects of
pirfenidone in the treatment of
idiopathic pulmonary ﬁbrosis?
To  the  Editor,
Idiopathic  pulmonary  ﬁbrosis  (IPF)  is  a  speciﬁc  form  of
chronic,  progressive  ﬁbrosing  pneumonia  of  unknown  cause,
occurring  primarily  in  older  adults  and  limited  to  the
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Classiﬁcation  of  the  Idiopathic  Interstitial  Pneumonias
statements,2 who  experienced  probable  toxicity  induced  by
pirfenidone.
The  ﬁrst  case  reports  a  62-year-old  female  non-smoker
diagnosed  with  IPF  (Possible  UIP  HRCT  and  UIP  pattern
in  surgical  lung  biopsy)  in  03-2011,  being  started  on  N-
acetylcisteine  600  mg  tid.  The  patient  was  started  on
pirfenidone  in  05-2014;  at  that  time  a  mild  restriction  was
observed  (FVC:  75%,  1760  mL,  TLCO:  76.3%).  From  the  time
she  was  started  on  pirfenidone,  she  complained  of  dyspep-
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aungs, with  a  very  poor  prognosis.
There  were  no  therapeutic  options  with  proven  efﬁ-
acy  until  recent  randomized  controlled  trials  have  shown
he  efﬁcacy  of  pirfenidone  and  nintedanib  in  reducing  the
ecline  rate  of  forced  vital  capacity  (FVC).3,4
Like  any  other  recently  introduced  drug,  the  whole  spec-
rum  of  the  side  effects  of  pirfenidone  is  still  unknown.
he  most  frequent  side  effects  reported  from  the  CAPACITY
nd  ASCEND  trials,3,5 the  follow-up  extension  study  RECAP6
nd  PASSPORT  registry  interim  results,7 are  gastrointesti-
al  (nausea,  diarrhea,  dyspepsia  and  vomiting),  cutaneous
rash,  photosensitivity),  headache,  dizziness  and  fatigue.
lthough  cough,  upper  airway  tract  infection  and  worsen-
ng  of  IPF  were  also  reported,  these  could  be  attributed  to
he  pathophysiology  of  IPF  per  se.
We  report  the  cases  of  2  patients  diagnosed  with  IPF
ccording  to  the  American  Thoracic  Society  (ATS)/European
espiratory  Society  (ERS)/Japanese  Respiratory  Soci-
ty/ALAT  consensus  statement  on  IPF1 and  the  2013
TS/ERS  update  of  the  International  Multidisciplinary
s
wia,  increasing  dyspnea  (modiﬁed  Medical  Research  Council
yspnea  scale  [mMRC]  2--3),  cough  and  wheezing.  On  phys-
cal  examination,  bilateral  basilar  crackles  and  expiratory
heezing  were  observed.  Blood  analysis  was  unremark-
ble  and  sputum  microbiological  exams  were  negative.
hest  radiography  was  similar  to  the  previous  ones.  Cardiac
eart  failure  and  pulmonary  hypertension  were  pursued  and
xcluded  by  echocardiogram,  and  NT  pro-BNP  was  within
ormal  range.  After  4  months  on  pirfenidone  the  patient
ept  complaining  of  wheezing  since  the  beginning  of  the
rug  and  troublesome  cough  not  alleviated  by  opioids;  func-
ional  decline  was  observed  (relative  FVC  drop  of  10%,  with
aintained  TLCO  value).  Pirfenidone  was  interrupted,  with
esolution  of  symptoms  after  one  month  and  improvement  of
VC  back  to  basal  values.  Reintroduction  of  pirfenidone  was
ttempted,  but  recurrence  of  symptoms  led  to  its  deﬁnitive
uspension.
The  second  case  reports  a  66-year-old  non-smoker
oman  diagnosed  with  IPF  in  07-2014  (Possible  UIP  HRCT,
